Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients

Autor: Azevedo, RS, Belli, C, Bassolli, L, Ferri, L, Perusini, MA, Enrico, A, Pereira, TDM, Junior, WFS, Buccheri, V, Pinheiro, RF, Magalhaes, SM, Schuster, S, Castelli, JB, Traina, F, Rocha, V, Velloso, EDRP

Publikováno v: In Clinical Lymphoma, Myeloma and Leukemia January 2022 22(1):e1-e6

AVALIAÇÃO CLÍNICA E POR NEXT GENERATION SEQUENCING DE INSUFICIÊNCIAS MEDULARES COM ENCURTAMENTO TELOMÉRICO

Autor: Rodrigues, TB, Pereira, TDM, Ramos, FSD, Santos, ALP, Vezozzo, DCP, Buccheri, V, Calado, R, Velloso, EDRP

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2024 46 Supplement 4:S91-S91

“REAL-WORLD” RESULTS OF HYPOMETHYLANT THERAPY IN MYELODYSPLASTIC SYNDROME, CHRONIC MYELOMONOCYTIC LEUKEMIA AND OLIGOBLASTIC ACUTE MYELOID LEUKEMIA

Autor: Castelo, LF, Bassolli, L, Pereira, TDM, Silva-Junior, WF, Buccheri, V, Marchi, L, Nukui, Y, Ferreira, C, Rocha, V, Velloso, E

Publikováno v: In Hematology, Transfusion and Cell Therapy October 2022 44 Supplement 2:S203-S204

Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers.

Autor: Castelo L; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil. Electronic address: fcastelo.lucas@gmail.com., da Silva WF; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Lincango M; Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/ Academia Nacional de Medicina, Buenos Aires, Argentina., Buccheri V; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Perusini A; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Arbelbide J; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Iastrebner M; Sanatorio Sagrado Corazón, Buenos Aires, Argentina., Gonzalez J; Hospital General de Agudos Carlos Durand, Buenos Aires, Argentina., Pereyra P; Hospital Nacional Alejandro Posadas, El Palomar, Provincia de Buenos Aires, Argentina., Pereira TDM; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Marchi LL; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Rocha V; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil., Belli CB; Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/ Academia Nacional de Medicina, Buenos Aires, Argentina., Velloso EDRP; Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil; Hospital Israelita Albert Einstein, Sao Paulo, SP, Brazil.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jun; Vol. 24 (6), pp. 407-411. Date of Electronic Publication: 2024 Feb 14.